UstekinumabVedolizumab
…Vedolizumab and Ustekinumab were first approved by our trust for treatment of patients with…
19articles mentioning drugs
57drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Risankizumab ×
Risankizumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Risankizumab
19 articles · page 2 of 2GolimumabBudesonideRisankizumabUstekinumabVedolizumabAdalimumabInfliximabThiopurinesIBDIBD-U+1 more
…b 44.3%, Adalimumab 27.9%, Vedolizumab 13.1%, Ustekinumab 9.8%, Golimumab 3.3% and Risankizumab 1.6%.The mean [±SD] gestational age at tr…
risankizumabRZBRZB-treatedCrohn’s diseaseCD
…g long-term efficacy and safety of interleukin-23 p19 inhibitor risankizumab (RZB) in patients (pts) with moderate to severe Crohn’s disease…
RisankizumabRZBRZB180RZB360
…Introduction Risankizumab (RZB), a high-affinity humanised IgG1 monoclonal antibody targe…
risankizumabmesalazinesecukinumabpsoriasisankylosing spondylitishidradenitis suppurativapsoriatic arthritisulcerative colitisinflammatory bowel diseaseMontreal E3+1 more
…ted. To ensure continued psoriasis control and treatment of UC, risankizumab, a selective IL-23 inhibitor, was administered at the standard …
tofacitinibUstekinumabvedolizumabrisankizumabinfliximabadalimumabulcerative colitisIBDinflammatory bowel diseaseCrohn’s disease+4 more
… led to 43.2% clinical remission in an Emirati CD cohort, while tofacitinib achieved clinical remission rates of 56.4% and 61.1% at 52 week…
AzathioprineUstekinumabUpadacitinibRisankizumabadalimumabVedolimumabinfliximabUlcerative colitisCrohn’s disease
…dalimumab,50% Vedolimumab,66%(n=4) had Ustekinumab,66%(n=4) had Azathioprine. All patients received UPA as monotherapy.UPA induction was adm…